Sarepta Therapeutics (NASDAQ:SRPT) Upgraded at BidaskClub

BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a research report sent to investors on Friday morning, BidAskClub reports.

Other analysts have also issued research reports about the stock. Cowen restated a buy rating and issued a $213.00 price target on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. Nomura lifted their price target on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the stock a buy rating in a research note on Thursday, February 28th. JMP Securities restated a buy rating and issued a $270.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, February 27th. Cantor Fitzgerald restated a buy rating on shares of Sarepta Therapeutics in a research note on Friday, February 22nd. Finally, Citigroup lifted their price target on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the stock a buy rating in a research note on Friday, March 1st. Twenty-one investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $201.71.

NASDAQ SRPT opened at $129.88 on Friday. Sarepta Therapeutics has a 52 week low of $95.21 and a 52 week high of $165.87. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. The firm has a market cap of $9.63 billion, a PE ratio of -23.79 and a beta of 1.96.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, topping analysts’ consensus estimates of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The business had revenue of $87.01 million for the quarter, compared to analysts’ expectations of $86.92 million. As a group, equities research analysts anticipate that Sarepta Therapeutics will post -4.36 earnings per share for the current year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director now owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.60% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in SRPT. Janus Henderson Group PLC increased its stake in Sarepta Therapeutics by 44.9% during the first quarter. Janus Henderson Group PLC now owns 2,666,043 shares of the biotechnology company’s stock valued at $317,766,000 after purchasing an additional 826,449 shares during the last quarter. FMR LLC grew its position in shares of Sarepta Therapeutics by 6.9% during the fourth quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock worth $1,152,977,000 after acquiring an additional 677,947 shares during the last quarter. OppenheimerFunds Inc. grew its position in shares of Sarepta Therapeutics by 505.6% during the first quarter. OppenheimerFunds Inc. now owns 768,868 shares of the biotechnology company’s stock worth $91,642,000 after acquiring an additional 641,904 shares during the last quarter. Norges Bank bought a new position in shares of Sarepta Therapeutics during the fourth quarter worth about $57,891,000. Finally, venBio Select Advisor LLC grew its position in shares of Sarepta Therapeutics by 35.1% during the fourth quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock worth $139,141,000 after acquiring an additional 331,500 shares during the last quarter.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Article: What factors cause inflation to rise?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit